HIF1A and lung carcinoma: These include agents such as aminoflavone shown to affect both HIF1A transcription and translation in breast cancer cell lines and xenograft models [88], GL331 that interferes with the activation of HIF1A promoter in a lung cancer cell model [89] and anthracyclines (such as idarubicin) that inhibit both HIF1A and EPAS1 transcription in pheochromocytoma cells and xenograft models [90].